Omega 3 en droge ogen

Posted

Omega 3 en droge ogen

Hier vindt u informatie over een onderzoek uit 2011 over Omega 3 en droge ogen

Het doel van deze website is om meer “evidence based research” informatie te geven over de Omega 3 vetzuren DHA, EPA en ALA. De makers van deze website kunnen niet aansprakelijk worden gesteld indien de informatie niet voldoet aan juistheid, volledigheid of effectiviteit. Het gebruik van de informatie geschiedt volledig op basis van eigen risico van de gebruiker.

Bron: http://www.dhaomega3.org/Eye-Visual-Health/Omega-3-Supplementation-Found-to-Alleviate-Dry-Eye-Syndrome

Omega 3 Research

OMEGA-3 SUPPLEMENTATION FOUND TO ALLEVIATE DRY EYE SYNDROME

17 JANUARY 2011

Reference:

Pilot , Prospective, Randomized , Double-masked , Placebo-controlled Clinical Trial of an Omega-3 Supplement for Dry Eye

Wojtowicz , J. et al., Cornea , 30 : in press , 2011

Dept. of Ophthamology , The University of Texas Southwestern Medical Ctr. at Dallas, Texas , USA

Summary:

Dry eye syndrome (DES) is an eye disease caused in part by decreased tear production with typical symptoms including assorted eye irritations including dryness, burning , itchy feeling , fatigue, pain, redness, and excessive sensitivity to bright light. If the condition becomes severe or is not successfully treated , it can produce complications leading to eye damage. The prevalence of DES increases with age in the population such that up to 30 % of people over age 50 in some regions suffer from this condition .

In the present study, patients with dry eye were treated with daily omega-3 supplementation consisting of 300 mg DHA plus 450 mg EPA plus 1000 mg flaxseed oil for a duration of 90 days. A total of 36 patients were clinically evaluated at baseline (entry) and at the end of the study. Tear secretion and tear volume was also assessed ( by Schrimer  testing and fluorophotometry ). When the supplementation trial ended, 70 % of the patients in the treatment group become symptom-free as compared to only 7% of those on the placebo (control) group. Further, the average tear production and tear volume was increased in the omega-3 group Dr. Holub’s Comments :

Is is noted that the omega-3 supplementation  regimen included DHA plus EPA from fish oil sources plus 1000 mg of flaxseed oil which would have been expected to provide approx. 500 mg of LNA (alpha-linolenic acid)  . Since DHA and EPA , and not LNA, are the precursors for the formation of the anti-inflammatory bioactive products known as resolvins and protectins , it remains to be determined to what extent , if any, the presence  of the plant-based omega-3 (ie, LNA from flax) may have contributed to the overall favourable effects. It is known that the human body has a very limited capacity to  metabolically convert LNA to EPA/DHA.  Very recently, research using a dry eye mouse model (after exposing the mice to dessicating conditions) has revealed that the direct topical application of resolvin E1 (as derived from EPA omega-3) was found to significantly improve tear production and to decrease inflammation (Li et al., J. Ocular Pharm. and Therapeutics, 26: 431-439 (2010). These findings suggest that such omega-3 products , resolvins and protectins, may have therapeutic potential in treating DES.